We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-7.52%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$250M
AUM Growth
-$48.9M
Cap. Flow
-$2.31M
Cap. Flow %
-0.92%
Top 10 Hldgs %
27.41%
Holding
148
New
30
Increased
17
Reduced
14
Closed
22

Top Buys

Rank Stock Value
1
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$7.25M
2
GH icon
Guardant Health
GH
+$5.2M
3
STAA icon
STAAR Surgical
STAA
+$4.83M
4
INGN icon
Inogen
INGN
+$4.14M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$3.53M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$7.56M
2
PEPLU
PepperLime Health Acquisition Corporation Unit
PEPLU
+$7.23M
3
GMED icon
Globus Medical
GMED
+$5.83M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$5.82M
5
BCYC
Bicycle Therapeutics
BCYC
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 73.54%
2 Financials 11.69%
3 Industrials 1.28%
4 Technology 0.99%
5 Consumer Discretionary 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$32.9B
$3.28M 1.31%
44,000
-6,000
-12% -$548K
XTNT icon
27
Xtant Medical Holdings
XTNT
$62.7M
$3.25M 1.3%
6,246,291
– –
TVRD
28
Tvardi Therapeutics
TVRD
$18.8M
$3.23M 1.29%
9,811
+5,228
+114% +$1.83M
PRCT icon
29
Procept Biorobotics
PRCT
$1.03B
$3.2M 1.28%
98,000
+50,923
+108% +$1.85M
KPTI icon
30
Karyopharm Therapeutics
KPTI
$46.2M
$3.16M 1.26%
46,667
+3,667
+9% +$336K
LIVN icon
31
LivaNova
LIVN
$4.64B
$3.12M 1.25%
50,000
– –
PTGX icon
32
CALL
Protagonist Therapeutics
PTGX
$8.81B
$2.89M 1.16%
365,100
+360,100
+7,202% +$4.35M
OCUL icon
33
Ocular Therapeutix
OCUL
$1.9B
$2.79M 1.12%
695,000
– –
EIGR
34
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.77M 1.11%
14,667
– –
GBT
35
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.72M 1.09%
85,000
+31,000
+57% +$907K
KURA icon
36
Kura Oncology
KURA
$852M
$2.69M 1.08%
+147,000
New +$2.11M
MASS icon
37
908 Devices
MASS
$346M
$2.57M 1.03%
+125,000
New +$2.1M
KRMD icon
38
KORU Medical Systems
KRMD
$197M
$2.52M 1.01%
995,500
– –
TMPM
39
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.52M 1.01%
254,000
– –
HRMY icon
40
Harmony Biosciences
HRMY
$2.25B
$2.44M 0.98%
+50,000
New +$2.25M
KROS icon
41
Keros Therapeutics
KROS
$202M
$2.43M 0.97%
88,000
-38,000
-30% -$1.67M
SWAV
42
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$2.29M 0.92%
12,000
-11,000
-48% -$1.94M
ISEE
43
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.27M 0.91%
236,000
– –
SRSA
44
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$2.23M 0.89%
225,000
– –
ACET icon
45
Adicet Bio
ACET
$86M
$2.19M 0.88%
9,375
-313
-3% -$68.7K
RNAM
46
DELISTED
Avidity Biosciences
RNAM
$2.18M 0.87%
150,000
-93,000
-38% -$1.38M
GOSS icon
47
Gossamer Bio
GOSS
$87.3M
$2.18M 0.87%
+260,000
New +$2.01M
NBIX icon
48
Neurocrine Biosciences
NBIX
$17B
$2.15M 0.86%
+22,000
New +$2.03M
COLL icon
49
Collegium Pharmaceutical
COLL
$1.15B
$2.06M 0.82%
+116,000
New +$1.95M
GIW
50
DELISTED
GigInternational1, Inc. Common Stock
GIW
$2.01M 0.8%
200,000
– –
1
2
3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
GC
Gruss & Co West Palm Beach, Florida $42.8M AUM 49.41% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return

Altium Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Altium Capital Management held 148 positions worth $250M, down 16% from $299M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Altium Capital Management's Q2 2022 filing shows 30 new, 17 increased, 14 reduced and 22 closed positions. Its largest new stake was PepperLime Health Acquisition Corporation Class A Ordinary Share: 735,000 shares worth $7.25M. The largest sale was Esperion Therapeutics, an estimated $7.56M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 78% a quarter earlier, followed by Financials and Industrials.

  • Altium Capital Management's largest Q2 2022 buy was PepperLime Health Acquisition Corporation Class A Ordinary Share: 735,000 shares worth $7.25M.
  • Altium Capital Management added most to Lantheus in Q2 2022, an estimated $3.03M increase.
  • Altium Capital Management's biggest Q2 2022 reduction was Esperion Therapeutics, cutting an estimated $7.56M.
  • Altium Capital Management fully exited PepperLime Health Acquisition Corporation Unit in Q2 2022, selling an estimated $7.23M.
  • Altium Capital Management's ten largest holdings make up 27% of its $250M portfolio in Q2 2022.
  • Altium Capital Management opened 30 new positions and closed 22 in Q2 2022.
  • Altium Capital Management's portfolio value fell 16% quarter-over-quarter to $250M.

Based on Altium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.